Home › Research › Inflammation and the immune system
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease
Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, León T et al.. Alzheimer's research & therapy, 2025-01-08
Topic: Amyloid, tau and blood-test diagnosis
Methods evoke and evoke+ are randomized, double-blind, placebo-controlled phase 3 trials investigating the efficacy, safety, and tolerability of once-daily oral semaglutide versus placebo in early-stage symptomatic AD. Results Enrollment was undertaken between May 18, 2021, and September 8, 2023.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., et al. (2025). evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-024-01666-7
Vancouver
Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, et al. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. Alzheimer's research & therapy. 2025. doi:10.1186/s13195-024-01666-7. PMID: 39780249.
BibTeX
@article{cummings2025-39780249,
author = {Cummings, J. L. and Atri, A. and Feldman, H. H. and Hansson, O. and Sano, M. and Knop, F. K. and Johannsen, P. and León, T. and others},
title = {{evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease}},
journal = {Alzheimer's research \& therapy},
year = {2025},
doi = {10.1186/s13195-024-01666-7},
pmid = {39780249},
url = {https://doi.org/10.1186/s13195-024-01666-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Methods evoke and evoke+ are randomized, double-blind, placebo-controlled phase 3 trials investigating the efficacy, safety, and tolerability of once-daily oral semaglutide versus placebo in early-stage symptomatic AD.
- Results Enrollment was undertaken between May 18, 2021, and September 8, 2023.
Why it matters
This paper sets out the design of evoke and evoke+, two large randomized, double-blind, placebo-controlled phase 3 trials of once-daily oral semaglutide versus placebo in people with early-stage symptomatic Alzheimer's disease. The trials enrolled participants between May 18, 2021, and September 8, 2023, to test efficacy, safety and tolerability. It is a design paper: it does not report whether semaglutide helped, so it should not be read as evidence that the drug works.
Study details
- Study designclinical trial
- Participants210
- Evidence strengthHigh
How this study scored 81/100
Published in a peer-reviewed journal, and it is a large phase 3 trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 210 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | 5 / 7 | Cited 157 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 52.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 6 / 6 | Cited 85.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 10 other studies in this library |
| Still being cited | 3 / 4 | Cited 157 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Philip Scheltens: h-index 181 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 15 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39780249) |
| Free to read | 2 / 2 | Free to read |
| Total | 81 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-024-01666-7
- PubMed: 39780249
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
In the news
1 news article on alzhub's news page cites this paper.
Later studies that cite this one
10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Inflammation and the immune system
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.